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ABSTRACT: We have previously reported that stabilization of the G-quadruplex structures in the HIV-1 long terminal repeat
(LTR) promoter suppresses viral transcription. Here we sought to develop new G-quadruplex ligands to be exploited as antiviral
compounds by enhancing binding toward the viral G-quadruplex structures. We synthesized naphthalene diimide derivatives with
a lateral expansion of the aromatic core. The new compounds were able to bind/stabilize the G-quadruplex to a high extent, and
some of them displayed clear-cut selectivity toward the viral G-quadruplexes with respect to the human telomeric G-
quadruplexes. This feature translated into low nanomolar anti-HIV-1 activity toward two viral strains and encouraging selectivity
indexes. The selectivity depended on speciﬁc recognition of LTR loop residues; the mechanism of action was ascribed to
inhibition of LTR promoter activity in cells. This is the ﬁrst example of G-quadruplex ligands that show increased selectivity
toward the viral G-quadruplexes and display remarkable antiviral activity.
■ INTRODUCTION
G-quadruplexes (G4s) are nucleic acids secondary structures
that may form in single-stranded G-rich sequences under
physiological conditions.1−3 Four Gs bind via Hoogsteen-type
hydrogen bonds base-pairing to yield G-quartets, which in turn
stack on top of each other to form the G4. G4 structures may
signiﬁcantly vary, both in terms of strand stoichiometry
(forming both inter- and intramolecular structures) and strand
orientation/topology. The presence of K+ cations speciﬁcally
supports G4 formation and stability.4−6 In the human genome
and in prokaryotes, G4 DNA motifs have been found in
telomeres, G-rich micro- and mini-satellites, near oncogene
promoters, and within the rDNA.7−12 Human G4 DNA motifs
have been reported to be associated with recombination prone
regions13 and to show mutational patterns that preserve the
potential to form G4 DNA structures.9 Misregulation of these
G4 structures has been associated with relevant human
neurological disorders.14−18 The identiﬁcation of G4 binding
proteins19 and their visualization in cells with antibody-based
technology20,21 have also provided convincing evidence of the
existence of cellular G4s in vivo.
Recently, the presence of G4s in viruses and their
involvement in virus key steps has also been provided.22 G4s
have been implicated in pathogenic mechanisms of the
Epstein−Barr virus23,24 and the SARS coronavirus.25 We and
other groups have identiﬁed functionally signiﬁcant G4s in the
Nef coding region26 and the unique long terminal repeat
(LTR) promoter27−29 of the human immunodeﬁciency virus
(HIV), the etiologic agent of the acquired immune deﬁciency
syndrome (AIDS). These studies have shown that G4 folding at
the LTR promoter decreased viral transcription with an eﬀect
that was augmented by a G4 ligand.27,30
The involvement of G4 structures in several human diseases
propelled the development of G4 ligands. Several aromatic
cores with protonable side chains bind the G4 conformation,
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such as porphyrins,31,32 acridines, such as 1 (BRACO-19,
Scheme 1),33,34 ﬂuoroquinolones35 anthraquinones, phenan-
throlines, quinacridines, carbazoles, bis-indole carboxamides,
triazoles, and benzimidazoles;36 natural compound derivatives,
such as berberine,37 telomestatin,38 quindolin,39 several tetra-
substituted perlyene tetracarboxylic, and water-soluble naph-
thalene diimide (NDIs).41−46 So far, the vast majority of
molecules has been tested against cellular G4s implicated in
tumor pathogenesis: some compounds showed interesting
antiproliferative properties;36 in particular, quarﬂoxin pro-
Scheme 1. Structure of BRACO-19 and Core-Extended NDIs (c-exNDIs) Reported in the Literature,44,48−51 and the New
Synthesized Water-Soluble c-exNDIs (lower right panel)
Scheme 2. Optimized Synthetic Protocol for the Preparation of Water-Soluble 2−11a
a(a) DMF, 70°C, 16 h, under N2; (b) N,N-dimethylpropylamine, MW, 150°C 3 min, closed vessel; (c) MeI, CHCl3, rt, 16 h.
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ceeded into phase II clinical trials, but its limited bioavailability
prevented further progress.35 Few molecules have been tested
also as antiviral agents:23,27,30,47 despite the low selectivity
indexes, these studies have shown the possibility to develop
antiviral molecules with a G-quadruplex-mediated mechanism
of action.
The lateral expansion of the NDI core provided by our
investigation may oﬀer an additional opportunity to enhance
both G4 binding potency and selectivity, discriminating G4
structures with diﬀerent accessibility to the edge quartets.
Examples that comprise the annulation of ﬁve- and six-
membered heterocyclic rings either on one side of the
NDI48,49 or on both sides have been reported (Scheme
1).50,51 Surprisingly, only one class of these core-extended
NDIs (c-exNDIs) has been engineered water-soluble to be
investigated as G4 ligand,44 the others have found applications
in the ﬁeld of material chemistry and as pH sensors.49−51
Because of the possibility to block HIV-1 transcription by
stabilizing the G4 structures present in the unique viral LTR
promoter, we here synthesized and tested a series of novel c-
exNDIs for both their binding to the LTR G4s and anti-HIV-1
activity. In these new structures, the NDI core has been merged
to the dihydrobenzophenazine polynuclear heterocycle (high-
lighted in red in Scheme 1). We proved that these derivatives
display binding and stabilization selectivity toward the viral G4s
as compared to a telomeric G4 and that this translates into a
therapeutic window where the compounds are active against
the virus but not toxic for the cell.
Figure 1. G4 stabilization by the c-exNDIs. (A) G4-forming sequences used in this study. (B) FRET analysis. ΔTm values of HIV-1 LTR G4-folded
sequences (LTR-III and LTR-IV), the G4-folded telomeric sequence (hTel), and a control double-stranded sequence (dsDNA) obtained upon
addition of equimolar amounts of 2−11 (0.25 μM). (C) Taq polymerase stop assay. Taq polymerization was performed in the presence/absence of
K+ and 2, as indicated, on the hTel, LTR-III, and LTR-IV templates, which were previously folded into G4. A control template unable to fold into G4
was also used (non-G4 cnt). Stop regions are highlighted by vertical bars. (D) Quantiﬁcation of the intensity of the stop bands obtained in the Taq
polymerase stop assay. Stop band intensity of the treated samples were normalized vs the untreated sample.
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■ RESULTS
Design and Synthesis of c-exNDIs. We have designed
and synthesized a small library of new and water-soluble c-
exNDIs (2−11, Scheme 2), where the NDI core has been
merged to the dihydrobenzophenazine polynuclear heterocycle
(highlighted in red in Scheme 1). The choice has been made
based on the pKa values of the N,N-dimethylpropan-amine side
chains: the pKa values are above 7 (pKa1 = 8.1, pKa2 = 8.6),
52
suggesting that the side chains are mainly protonated under
physiological conditions. This aspect ensures good solubilizing
properties, reducing self-aggregations. We discharged the
shorter N,N-dimethylthyl-amine side chains, as their pKa values
are much lower (pKa1 = 5.6, pKa2 = 7.4). The c-exNDIs are
structurally characterized by a larger ﬂat core than the NDIs.
This feature should improve π-stacking interaction implement-
ing the binding to the G4. Indeed, DFT calculation performed
at B3LYP/6-31+G(d,p) level of theory in gas phase indicated
that the dimension of the c-exNDI core supported a more
extensive overlap to the quartet of the G4 structure
(Supporting Information, Figure S1). Enhancement of the
ligand steric hindrance accessing the outside G4 quartets might
oﬀer an opportunity to implement selectivity as well.
Furthermore, the proposed structural extension on the NDI
scaﬀold should merge the useful optoelectronic properties
(absorption, emission, and singlet oxygen sensitizer) of
functionalized NDIs to those of substituted dihydrobenzophe-
nazines. Compounds with both H and Br substituents at the Y
position were considered to evaluate the eﬀect of a bulky
substituent (Br) at this position. To synthesize the c-exNDIs,
we developed the synthetic protocol highlighted in Scheme 2.
According to published methods, the imidation reaction of the
readily available 2,6-dibromo-1,4,5,8-naphthalenetetracarboxylic
dianhydride yielded the 2,6-dibromo-substituted NDI, under
acidic conditions, in almost quantitative yield. Subsequently, a
two-step protocol starting from a nucleophilic aromatic
substitution (SNAr) in the presence of an excess (2.5 equiv)
of ortho-diaminophenyl derivatives in DMF as solvent at 70 °C
for 16 h aﬀorded a 60:40 mixture of monobrominated and
debrominated products in an overall quantitative yield. The
ring closing reaction following the SNAr in one pot (step a, in
Scheme 2) occurred through a Tchitchibabin mechanism, with
the elimination of hydride favored by the formation of a six-
membered ring. The second SNAr on the remaining aromatic
bromide was carried out by dissolving 3 in neat N1,N1-
dimethylpropane-1,3-diamine. To improve the reaction yield,
we optimized a microwave-assisted protocol (150 °C, 200 psi,
250 bar, 200 W, 3 min, sealed reaction vessels) to give product
9, which crystallized from the reaction mixture. We achieved
the synthesis of the permanently charged quaternary
ammonium salts 10 and 11 with a classical exhaustive
methylation, in the presence of MeI at rt for 16 h. All the
synthesized ligands (2−11) were puriﬁed by preparative HPLC
(CH3CN:H2O and 0.1% CF3COOH as eluent). Further anion
exchange yielded 2−9 as hydrochloride salts. On the contrary,
10 and 11 were investigated as iodide quaternary ammonium
salts.
c-exNDIs Greatly Stabilize G4 with a Preference for
the LTR Conformations vs the Telomeric Sequence. To
detect the ability of the new c-exNDIs to bind and stabilize the
G4 conformations of the HIV-1 LTR promoter, two G4-
forming LTR sequences were employed: LTR-III and LTR-IV,
both composed of four GGG tracts (Figure 1A). When
embedded within the full-length G-rich sequence of the LTR
promoter, LTR-III is the most stable G4, while LTR-IV folds
when induced by G4 ligands.27 A FRET melting assay was
performed to assess the degree of stabilization of the LTR-III
and LTR-IV G4 by c-exNDIs. The minimal intramolecular G4-
forming human telomeric (hTel) sequence (Figure 1A) was
employed to evaluate the activity of the c-exNDIs on one of the
most highly represented and accessible cellular G4: in fact, the
TTAGGG repeat is present as 2000−3000 double-stranded
(ds) and 50−200 single-stranded sequences at the human
telomeres.53 A double-stranded (ds) DNA was also added to
address speciﬁcity toward the G4 conformation (Supporting
Information, Table S1). While this kind of assay is typically
performed using molar excess of the tested compounds, we
here initially employed equimolar amounts of the target DNA
sequence and compounds (i.e., 0.25 μM) to better diﬀerentiate
the stabilization eﬃciency among the diﬀerent c-exNDIs. The
melting temperatures of the LTR-III, LTR-IV, hTel, and
dsDNA G4 conformations were suﬃciently similar (66.9, 61.9,
66.9, and 66.5 °C, respectively) to allow a meaningful
comparison. In the presence of the c-exNDIs, a marked
increase in the stabilization of the G4-forming oligonucleotides
was observed (Figure 1B and Supporting Information, Table
S2). Among the tested c-exNDIs, 2, 3, 4, 10, and 11 were the
most eﬃcient ligands, with a stabilization on LTR-IV G4 of
10−16 °C at equimolar amounts. At 4-fold c-exNDI:DNA
molar ratio, the stabilization increased to above 25 °C, which is
the maximum increase measurable in these settings (data not
shown). The other c-exNDIs showed intermediate (4 °C ≤
ΔTm < 7 °C, 5, 6, and 7), or low (ΔTm < 4 °C, 8 and 9) level
of stabilization on LTR-IV G4. Compounds 2 and 10 stabilized
LTR-III G4 above 10 °C. Among the G4 structures, hTel G4
was the least eﬃciently stabilized, whereas stabilization on
dsDNA was negligible. Only compounds 10 and 11 displayed a
signiﬁcant stabilization on dsDNA, indicating that the presence
of two permanent charges (the quaternary ammonium
moieties) favors an unspeciﬁc binding to the negatively charged
nucleic acid. In general, the H series of all derivatives (Y = H, 2,
4, 6, 10; Scheme 2) was more active and more selective for the
viral G4s compared to the Br substituted ones (Y = Br, 3, 5, 7,
8; Scheme 2). Compounds 2, 3, and 10 exhibited a diﬀerence
in stabilization of LTR-IV G4s vs hTel G4 equal or above 6 °C,
which roughly corresponds to 40% of the overall stabilization
eﬃciency (Figure 1B and Supporting Information, Table S2).
Because oligonucleotides used for FRET analysis display
ﬂuorophore-modiﬁed ends that may inﬂuence the measured
stabilization, additional techniques using label-free oligonucleo-
tides were employed. Compound 2, a representative of the best
ligands, was assayed by circular dichroism (CD) on LTR-IV,
LTR-III, and hTel G4s. At 4:1 c-exNDI:DNA ratio, a
stabilization higher than 27 °C was obtained on both LTR-III
and LTR-IV (Supporting Information, Figures S2A and S2B),
while hTel G4s was stabilized by only 19.9 °C (Supporting
Information, Figure S2C), conﬁrming a preference for the viral
G4s. A Taq polymerase stop assay was performed on the LTR-
III, LTR-IV, and hTel templates. A control template unable to
fold into G4 was used to exclude unspeciﬁc inhibition of the
polymerase enzyme by the c-exNDI. Compound 2 induced an
intense stop site at the most 3′ G tract in each G4-forming
template (Figure 1C), indicating eﬀective stabilization of the
G4 conformation by the compound. This eﬀect was
signiﬁcantly more relevant on the viral sequences vs the
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Figure 2. Aﬃnity and binding site analysis. (A) ESI/MS competition assay. Representative spectrum. Equimolar amounts of LTR-III and hTel were
incubated with 2-fold excess of 2 and analyzed by ESI/MS. The identity of m/z signals is shown above each signal. RI stands for relative intensity.
(B) SPR analysis of 2 binding toward the LTRs and hTel G4s. Representative sensorgram of 2 binding to LTR-III G4. Biosensor data were collected
at 25 °C; the compound was injected at increasing concentrations (26, 40, 59, 89, 133, 200 nM). Sensorgrams are shown as gray lines. Dotted black
lines represent local 1:1 binding ﬁts obtained for a calculated Rmax. (C,D) CL-mediated footprinting. LTR-IV (C) and LTR-III (D) oligonucleotides
were G4 folded, incubated with increasing amounts of 2 (lanes 5−13), alkylated with CL (CL lanes), and subjected to hot piperidine treatment (PIP
lanes) to induce cleavage of the phosphodiester bond at the alkylated bases. (C) Lanes 1−4 are control lanes not treated with the c-exNDI. The
symbols * and ○ indicate base protection and exposure, respectively. M is a marker lane obtained by the Maxam and Gilbert sequencing of the
oligonucleotides. The oligonucleotide sequence is shown on the left. The vertical dotted bar indicates the region of the LTR-III shared with LTR-IV.
(E) Schematics of the LTR-IV and LTR-III G4 conformations. The represented LTR-IV G4 topology has been solved by NMR (PDB code 2N4Y);
the shown LTR-III G4 conformation derives from previous low resolution structural data.27
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telomeric template (Figure 1D), conﬁrming again a preferential
stabilization of the viral G4s.
The above techniques evaluated stabilization of the G4
conformation as an indicator of the eﬃciency of the interaction
of the ligands with the tested G4 structures. Binding aﬃnity was
next directly assessed by two diﬀerent methods.
Competition electrospray ionization mass spectrometry
(ESI-MS) experiments54−56 allowed establishment of the
relative aﬃnity of the c-exNDIs toward the G4 sequences.
We ﬁrst conﬁrmed by CD analysis that in the buﬀer conditions
used for the ESI/MS experiments the topology of the G4-
folded oligonucleotides did not signiﬁcantly modify (Support-
ing Information, Figure S3) Equimolar amounts of LTR-III/
hTel, LTR-IV/hTel, and LTR-III/LTR-IV G4s were incubated
with 2-fold molar excess of compounds 2 or 4. Because ESI/
MS transfers intact biomolecules complexes in the gas phase
and signal intensity is proportional to the abundance of each
species in solution, the ratio between m/z signals of each bound
species and the corresponding bound and free G4 (Figure 2A)
was calculated (Table 1). While LTR-III and LTR-IV were
detected mostly as all-bound species, hTel was mostly unbound
(Figure 2A, and Supporting Information, Figures S4A and
S4B). This analysis clearly shows that our c-exNDIs
preferentially bind the two viral sequences over the telomeric
sequence. To corroborate the selectivity toward the viral
sequences, two additional cellular G4 folding sequences were
evaluated: c-kit257 and c-myc.32 The LTR G4s were preferred
over c-kit2 G4 by both compounds; in the case of c-myc G4,
compound 4 preferentially bound to the LTR G4s, whereas
compound 2 showed more intense binding to c-myc (Table 1).
Therefore, we conﬁrmed a general, even though not absolute,
selectivity toward the LTR G4s. It is also possible that the
much higher stability of the c-myc G4 (Tm > 95 °C) vs the
stability of the other tested G4s (LTR-III 66.9 °C, LTR-IV 61.9
°C, c-kit2 72.1 °C) played a role in this result. When the two
LTR G4s were competed with each other, the LTR-III
sequence was preferred. At 2-fold excess of compound, LTR-
III bound up to two molecules of compounds, whereas only
one molecule was obtained for both LTR-IV and hTel (Figure
2, and Supporting Information, Figure S5). At saturating
concentrations (10-fold molar excess), three molecules were
bound to LTR-III G4, whereas up to two molecules could bind
LTR-IV and hTel G4s (Supporting Information, Figure S5).
Next, absolute aﬃnity of 2 was measured by surface plasmon
resonance (SPR) toward the three G4-folded sequences. This
analysis conﬁrmed that LTR-III G4 displays the highest binding
aﬃnity (KD 3.2 nM), followed by LTR-IV G4 (KD 6.1 nM);
hTel G4 exhibited the lowest aﬃnity (KD 13.1 nM) (Figure 2B,
and Supporting Information, Figure S6). The binding aﬃnity of
the Br derivatives with each of the substituents in position R
against LTR-IV was next assessed. Compounds 3 and 5 had KD
values similar to that of 2 (KD 6.6 and 5.9 nM, respectively), 10
displayed an increased binding aﬃnity (KD 1.7 nM), whereas 7
and 11 showed the lowest aﬃnity (KD 21.6 and 12.9 nM,
respectively). These data are in line with the stabilization
properties observed for these derivatives by FRET and CD
analysis and conﬁrm the improved and reduced recognition
properties of the c-exNDIs exhibiting permanent dicationic
(10) and neutral or monocationic charge states (7),
respectively, under physiological conditions. They also conﬁrm
that a bulky substituent in position Y of the NDI core (11,
Scheme 2) highly reduces binding, whereas a NO2 group in
position R maintains excellent binding properties (5, Scheme
2).
We reasoned that the observed biased aﬃnity for the LTR
sequences could derive by speciﬁc binding of the c-exNDIs to
structural/sequence features shared by the LTR G4s. To this
end, we evaluated the protection exerted by compound 2 over
residues of the LTR G4s against clerocidin (CL). This molecule
has been shown to alkylate DNA single-stranded G, C, and A
bases58,59 and to be able to predict G4 structural folding.60
Labeled oligonucleotides were folded, treated with increasing
amounts of 2, exposed to CL, and further treated with
piperidine to highlight CL-alkylated sites. In these settings, we
expected to visualize only loop bases bound by the c-exNDI
because base-paired Gs involved in G-quartet formation would
not be available to CL alkylation, independently of the presence
of the compound. The NMR structure of LTR-IV has been
solved (PDB code 2N4Y), and therefore we were able to assess
that nucleotides aﬀected by the presence of the c-exNDI were
in two loops of the structure: in particular, in the ACTG loop
the A base was protected, whereas C and G were exposed; in
the 1-base-loop, the C base was exposed (Figure 2C and 2E).
The structure of LTR-III has not been solved yet, however,
previous data indicated that this G4 can fold into diﬀerent
conformations, the main one of which is likely the one depicted
in Figure 2E, as detected by low-resolution structural data.27 In
this case, we observed protection of the C base in the ACTG
loop (Figure 2D), which is shared with the LTR-IV sequence
(see Figure 1A); three additional residues (C, C, and G) were
protected in the 11-base-loop (Figure 2D and 2E). Protection
and exposure of residues indicated speciﬁc interaction of 2 at
the aﬀected LTR sites. Interestingly, unique LTR loops and in
particular the ACTG loop shared by both LTR-III and LTR-IV,
and absent in the telomeric sequence, were involved, indicating
that these are likely the moieties that induce selectivity. We
cannot exclude that other regions are bound by the c-exNDI,
but probably the interaction at other sites is less stable or more
Table 1. Relative Binding Aﬃnity of 2 and 4 for the LTR-III, LTR-IV, hTel, c-kit2 (kit), and c-myc (myc) G4-Folded
Oligonucleotides
binding aﬃnity68
c-exNDI 2 c-exNDI 4
competing G4s LTR-III LTR-IV cell G4 (hTel, kit, or myc) LTR-III LTR-IV cell G4 (hTel, kit, or myc)
LTR-III/hTel 80 10 82 10
LTR-IV/hTel 52 25 75 18
LTR-III/LTR-IV 71 25 80 68
LTR-III/kit 33 12 54 18
LTR-IV/kit 25 9 55 23
LTR-III/myc 39 45 51 37
LTR-IV/myc 25 44 71 45
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dynamic so that a clear protection/exposure could not be
observed.
The Extended Core NDIs Display Anti-HIV-1 Activity
at Nanomolar Concentrations. We have previously shown
that the HIV-1 viral promoter folds into dynamic G4s and that
stabilization of these G4 conformations by the G4 ligand 1
represses viral transcription and virus production in infected
cells with IC50 (the concentration required to inhibit 50% of
virus production) in the low μM range.27,30 The average
selectivity index (SI) for 1 was 12. Given the c-exNDI binding/
stabilization selectivity observed in vitro for the viral G4s vs the
cellular G4, we set out to investigate the anti-HIV-1 activity of
the newly synthesized c-exNDI derivatives. Compound entry
was preliminarily measured by phase contrast and ﬂuorescence
microscopy, taking advantage of the blue-colored c-exNDI dyes
(λabs = 555 and 600 nm, for the unsubstituted 2) and their red
ﬂuorescence emission (λem = 610 and 655 nm, for 2). After 30
min of incubation, compounds concentrated into the cell
(Supporting Information, Figure S7). We next treated infected
cells with increasing amounts of compounds and measured
virus production; concurrently, the cytotoxic concentration
(CC50) of the c-exNDIs in the same conditions but on
uninfected cells was measured by MTT assay. All compounds
were tested against the HIV-1 NL4-3 strain, which is a X4
strain. Results are reported in Table 2. Compounds 2, 3, 4, and
5 displayed inhibitory concentration (IC50) values below 25
nM. Compound 2 displayed a promising SI of 40, the best
among the tested c-exNDIs, whereas SI values of compound 3,
4, and 5 were around 20, again superior to 1. Derivatives 6 and
7 exhibited low activity and low cytotoxicity, while 9 showed
the worst combination with low activity, high cytotoxicity, and
SI of 2.2. We also evaluated the range of concentration
(therapeutic window or TW), at which we obtained antiviral
activity paralleled by less than 80% cytotoxicity. As shown in
Figure 3A, 2 displayed the widest TW (3.9−250 nM); 4 and 5
also showed interesting TW values; TW concentrations for 6
and 7, which are likely to be mainly monoanionic under
physiological conditions as both the (CH2)3NHMe2
+ moieties
exhibit a pKa >8.1,
52 were in the μM range; no TW was
observed for 8 and 9 (Table 1). Finally, 10 and 11, containing
two quaternary ammonium moieties, did not display any
antiviral or cytotoxic activity likely due to their inability to enter
the cells, as already shown for NDIs with permanent positive
charges.61 Compound 2 and 3 were also tested on the HIV-1
BaL strain, a R5 strain with a diﬀerent tropism. In this case, IC50
values below 40 nM were obtained, with SI of 14 for the H
derivative (Table 1). Note that the H series of all derivatives
was more active than the Br substituted one. Moreover, all
compounds displayed CC50 values higher than 2 μM against a
human ﬁbroblast cell line.
The NDIs Derivatives Inhibit HIV-1 LTR Promoter
Activity. It has been reported that compounds with multiple
positive charges can block viral entry by interfering with the
CXCR4 coreceptor.62 To rule out this unspeciﬁc mechanism of
action of the c-exNDI, we treated TZM-bl cells at 0, 1, and 2 h
post infection (pi) with compound 2 and tested virus
production at 31 h pi. No signiﬁcant diﬀerence in the activity
of the compound was observed at the tested times (Figure 3B).
Zidovudine (AZT), a reference drug that targets the reverse
transcriptase step,63 displayed a behavior similar to that of the
c-exNDI, maintaining activity from 0 to 2 h pi. In contrast,
dextran sulfate (DS), a reference entry inhibitor,64 exhibited
antiviral eﬀect only when added at 0 h pi. (Figure 3B). These
data indicate that the initial steps are not targeted by 2, which is
thus active at/after 2 h pi, i.e., after the entry process has
occurred.
We next tested the ability of 2 to reduce the activity of the
HIV-1 LTR promoter in an EGFP reporter assay in HeLa-tat-
III cells, which is a cell line stably transfected with a plasmid
embedding the EGFP coding region under the control of the
HIV-1 LTR promoter. Cells were treated with increasing
concentrations of the c-exNDI, and the intensity of EGFP
ﬂuorescence was assessed by FACS analysis. A steady decrease
in the mean levels of EGFP was observed at noncytotoxic
concentrations of 2 (up to 60% of inhibition) (Figure 3C). To
check if the activity of the c-exNDI at the LTR promoter was
speciﬁc for the G4 conformation, two point mutations that
abolish G4 folding were introduced in the LTR sequence (M4
+ 5 LTR).27 The wt LTR and M4 + 5 LTR luciferase reporter
plasmids were transiently transfected into 293T cells either
alone or in the presence of increasing amounts of compound 2,
and the luciferase signal was measured. Again, an important
inhibition of LTR activity was observed on the wt LTR (up to
65% inhibition), whereas no eﬀect was detected on the non-
G4-forming mutant LTR sequence (Figure 3D). These data
indicate a G4-mediated inhibition of the viral promoter by the
c-exNDI.
Table 2. Antiviral Eﬀects of the c-exNDI Derivatives and the Control 1 against Two HIV-1 Strains in TZM-bl Cellsa
IC50 (nM) SI TW (nM)
c-exNDI HIV-1 strain NL4-3 HIV-1 strain BaL CC50 (nM) HIV-1 strain NL4-3 HIV-1 strain BaL HIV-1 strain NL4-3 HIV-1 strain BaL
2 13.2 ± 0.1 36.2 ± 4.3 532.0 ± 11.7 40 14 3.9−250.0 15.6−250.0
3 15.7 ± 2.1 32.5 ± 7.1 343.2 ± 32.2 22 11 7.8−125.0 15.6−125.0
4 11.0 ± 0.3 nd 188.0 ± 4.08 17 nd 3.9−125.0 nd
5 23.0 ± 1.3 nd 439.0 ± 10.7 19 nd 15.6−250.0 nd
6 975.3 ± 16.2 nd > 5000 >5 nd 800−5000 nd
7 862.6 ± 31.5 nd > 5000 >6 nd 800−5000 nd
8 63.5 ± 4.8 nd 458.1 ± 54.0 7.2 nd no TW nd
9 814.3 ± 36.4 nd 1759.9 ± 62.5 2.2 nd no TW nd
10 >5000 nd >5000 nd no TW nd
11 > 000 nd >5000 nd no TW nd
1 3400 ± 140b nd >12000b >3.5 nd 3000−12000 nd
aNL4−3 and BaL are X4 and R5, respectively, HIV-1 strains. IC50 is the compound concentration required to inhibit 50% of HIV-1 production;
CC50 is the compound concentration at which 50% of cell toxicity is observed; SI is the selectivity index; TW is the therapeutic window
concentration. nd stands for “not determined”. bindicates values previously reported.27
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■ DISCUSSION AND CONCLUSIONS
We have here shown the synthesis, G4 binding properties, and
antiviral activity of a new series of NDI derivatives with an
extended aromatic core. First, most of the new compounds
displayed improved stabilization on G4 structures, with
substantial increments in Tm above values previously reported
for NDI derivatives.41−46 This feature is an indication that the
expansion of the aromatic surface allows a more eﬀective
recognition of the G4 structure. This may be due to a more
extensive overlap to the quartet of the G4 structure, as inferred
by the dimension of the c-exNDI core, evaluated by DFT
calculation (Supporting Information, Figure S1). Second, these
compounds exhibited a very promising antiviral activity.
Compared to 1,30 the best antiviral 2−5 showed improved
IC50 values (in the low nM vs low μM range). This feature may
derive from the selectivity observed in vitro for the LTR G4s
over the telomeric G4 structures. The viral and telomeric G4s
are likely the two most abundant DNA G4 species in the cell
during infection, therefore a preferential eﬀect on the viral G4s
would result in higher antiviral activity and lower cytotoxicity,
as observed. The c-exNDIs displayed both selective binding
aﬃnity and stabilization for the viral G4s. Between the two
LTR G4s, the LTR-III sequence was most eﬃciently bound by
2, as measured by ESI/MS and SPR. Even though LTR-III (38
nts) and LTR-IV (29 nts) display an identical number of G-
quartets, LTR-III oﬀers longer loops that may accommodate
additional molecules and therefore may display increased
binding aﬃnity. Indeed, at saturating concentrations, binding
of up to three c-exNDI molecules was observed by ESI/MS
with LTR-III compared to two molecules for LTR-IV. In
Figure 3. Antiviral activity of c-exNDIs and mechanism of action. (A) TZM-bl cells were infected with HIV-1 NL4-3 strain and treated with
increasing concentrations (3.9−1000 nM) of the c-exNDIs. Uninfected cells were treated in the same conditions. Antiviral activity, expressed as
relative luciferase units (RLU), was measured on infected cells, while cell viability was in parallel obtained with a MTT assay on the uninfected cells.
The vertical dotted lines deﬁne the therapeutic window (TW) where the compound is active against the virus and not toxic against the cells. This
ﬁgure is representative of the antiviral/cytotoxicity/TW experiments performed with the whole series of c-exNDI compounds. (B) Entry assay.
TZM-bl cells were treated with the compound 2 (50−100 nM), AZT (0.5 μg/mL), or the entry inhibitor DS (100 μg/mL) at 0, 1, or 2 h pi. Virus
production was measured at 31 h pi as RLU. The control depicts cells infected with the virus lacking compound treatment. (C) Eﬀect of 2 on the
LTR promoter activity compared to cytotoxicity. HeLa cells with a stably transfected LTR-EGFP reporter plasmid were treated with increasing
concentrations of 2 (62.5−250 nM). EGFP mean was measured by FACS analysis. Cytotoxicity was estimate in parallel by gating on forward scatter
(FSC) vs side scatter (SSC) using untreated cells as reference. (D) Speciﬁcity of the 2-induced inhibition of LTR promoter activity on the G4 LTR
conformation. 293T cells were transiently transfected with plasmids with the wt or M4 + 5 mutant LTR promoter sequence upstream a luciferase
reporter gene. Luciferase signals were measured as a function of increasing 2 amounts and normalized to total protein content.
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addition, two loops in both LTR-III and LTR-IV G4s were
shown to be involved in c-exNDI interaction by footprinting
analyses. We suggest that the compounds interact with the edge
G-quartets through the core NDI planar aromatic surface, while
the extended moiety and side chains interact with the side
loops, aﬀording selectivity toward the LTR G4s. To our
knowledge, this is the ﬁrst example of this type of selectivity
based on chemical recognition of speciﬁc residues; in fact,
previously reported selectivity rather relied on the recognition
of a G4 conformation.65
Analysis of the binding activity of the series of c-exNDIs led
us to the following structure−activity relationship (SAR)
conclusions: (i) the nonextended side of the c-exNDI core
[position Y (Scheme 1)], lacking substituents as the
introduction of an aminoalkyl side chain, highly hinders
stabilization of the G4 structures (i.e., 9); (ii) Br is allowed
as Y substituent, but it lowers binding and selectivity toward the
viral sequences. The Br group may both hinder speciﬁc
interactions (hence lower selectivity) and partially distort the
aromatic core from planarity (hence lower G4 binding); (iii)
the pyridine ring in place of the benzene in the extended core is
strongly detrimental (compound 8). The fair antiviral activity is
paralleled by moderate cytotoxicity, allowing no TW, possibly
due to oﬀ-target activity; (iv) the NO2 moiety is allowed
(compounds 4 and 5) as compound 4 is the most powerful and
selective ligand toward LTR-III; (v) the negatively charged
carboxylate group decrease the electrostatic component of the
binding to the DNA G4s (compounds 6 and 7); (vi) on the
contrary, the permanently positively charged ammonium
groups extensively increase binding to the target G4s by adding
electrostatic interaction (compounds 10 and 11). However,
compounds with permanent charges are not suitable for cell
entry and hence cannot be exploited for antiviral purposes. A
scheme of the chemical properties that lead to high-aﬃnity
recognition and selectivity of the c-exNDI binders is reported
in the graphical abstract.
In conclusion, we have reported a new class of G4 ligands
able to discriminate G4 structures based on the chemical
recognition of structural features that are unique to the selected
G4 sequences. On one hand this approach opens the possibility
to develop anti-HIV compounds with a new mechanism of
action that may complement current clinical AIDS therapies;
on the other hand, our work clearly highlights the possibility to
selectively recognize G4 structures with small molecules,
prompting the search and development of G4 ligands speciﬁc
for G4s implicated in several important human diseases.
■ EXPERIMENTAL SECTION
Materials and General Procedures. Reagents, oligonucleotides,
solvents, and chemicals were purchased from Alfa Aesar or Sigma-
Aldrich and were used as supplied without further puriﬁcation. TLC
analysis was carried out on silica gel (Merck 60F-254) with
visualization at 254 and 366 nm. HPLC analysis and puriﬁcations
were performed using two diﬀerent HPLC: Waters system combining
a Delta 600 PUMP, a 2489 UV/vis detector and Fraction Collector III
(for preparative and analytical), and an Agilent system series 1260 (for
analytical). The analytical column was XSelect CSH Phenyl-Hexyl
(150 mm × 4.6 mm) (Waters). The preparative column was XSelect
CSH Prep phenyl−hexyl 5 μm (150 mm × 30 mm) (Waters). Flows
were 1 or 1.4 mL/min for analytical and 27 mL/min for preparative.
For the analytical analysis were used the following method A:
(aqueous solvent: 0.1% triﬂuoroacetic acid in water; organic solvent,
acetonitrile); method A = 1 mL/min, isocratic ﬂow over 2 min 95% of
aqueous solvent; gradient, 95% aqueous, gradually to 40% aqueous
over 12 min and at the end an isocratic ﬂow over 4 min. For the
preparative puriﬁcation was used the following method B: (aqueous
solvent: 0.1% triﬂuoroacetic acid in water; organic solvent,
acetonitrile); Method B = 27 mL/min, isocratic ﬂow over 4 min
95% of aqueous solvent; gradient, 95% aqueous, gradually to 70%
aqueous over 16 min and at the end an isocratic ﬂow over 4 min). 1H ,
13C NMR spectra were recorded on a Bruker ADVANCE 300 MHz
spectrometer. The potentiometric titrations were made with a
Radiometer TitraLab 90 titration system. UV/vis spectra were run
on a Varian Cary 100 SCAN spectrophotometer with quartz cuvettes
of the appropriate path length (0.1−1 cm) at 25.0 ± 0.1 °C. Emission
spectra were recorded on a PerkinElmer LS 50B instrument.
Chemistry. General Methods. Synthesis of Intermediates and
Final Ligands. Br2NDI has been synthesized according to the
published procedure.52 The new ligands (2−11) were analyzed by
HPLC (see Supporting Information, HPLC Purity Data), conﬁrming
≥97.6% purity.
Nucleophilic Aromatic Substitution/Tchichibabin Reaction: Syn-
thesis of 2−5, 8. The starting NDI (0.5 mmol) was dissolved into 20
mL of DMF in a round-bottom ﬂask together with 1.0 mmol of o-
phenyl-diamine derivatives, the mixture was stirred at 45 °C for 16 h
under argon. The resulting dark-violet solution was basiﬁed with
sodium bicarbonate aqueous solution and extracted with three portion
of CHCl3 (50 mL). The organic layers were collected, dried on
NaSO4, and evaporated under vacuo. The crude product was analyzed
and puriﬁed by HPLC chromatography (CH3CN:H2O 0.1%TFA)
according to analytical method A and preparative method B. HCl 1 M
solution was added to each chromatographic portion. Solvent
evaporation under vacuum aﬀorded the product as hydrochloride salt.
2·2HCl. Yield = 25.2%; dark-violet solid; mp dec >200 °C. 1H NMR
(300 MHz, CD3OD): 7.74 (s, 2H), 7.11 (dd, J = 3.3, 5.7 Hz, 2H), 6.89
(dd, J = 3.3, 5.7 Hz, 2H), 4.06 (m, 4H); 3.26 (m, 4H), 2.94 (s, 12H),
2.14 (m, 4H). 13C NMR (75 MHz, CD3OD): 166.4, 164.3, 143.2,
128.7, 128.0, 127.0, 125.9, 123.0, 118.2, 96.0, 57.0, 56.0, 43.9, 38.5,
38.2, 24.9, 24.2. Anal. Calcd for C30H34Cl2N6O4: C, 58.73; H, 5.59; Cl,
11.56; N, 13.70; O, 10.43. Found: C, 58.87; H, 5.51; N, 13.52.
3·2HCl. Yield = 19.4%; dark-violet solid; mp dec >200 °C. 1H NMR
(300 MHz, CD3OD): 8.1 (s, 1H), 7.15 (dd, J = 3.4, 6.0 Hz, 2H), 7.03
(dd, J = 3.4, 6.0 Hz, 2H), 4.17 (m, 4H), 3.25 (m, 4H), 2.94 (s, 12H),
2.16 (m, 4H). 13C NMR (75 MHz, CD3OD): 166.5, 166.1, 163.9,
163.6, 152.4, 144.3, 132.5, 130.3, 129.0, 128.9, 128.3, 128.1, 126.6,
123.1, 121.1, 120.4, 118.4, 118.2, 97.0, 79.8, 57.1, 43.9, 38.7, 38.5, 24.9,
24.7. Anal. Calcd for C30H33BrCl2N6O4: C, 52.04; H, 4.80; Br, 11.54;
Cl, 10.24; N, 12.14; O, 9.24. Found: C, 52.17; H, 4.81; N, 12.12.
4·2HCl. Yield = 11.2%; dark-violet solid; mp dec >200 °C. 1H NMR
(300 MHz, CD3OD): 8.04 (s, 2H), 7.88 (d, J = 6.6 Hz, 1H), 7.84 (1H,
s), 7.07 (d, J = 6.5 Hz, 1H), 4.2 (bs, 4H), 3.27 (m, 4H), 2.94 (s, 12H),
2.17 (m, 4H). 13C NMR (75 MHz, CD3OD):166.9, 166.7, 164.5,
134.6, 132.1, 129.6, 127.3, 127.2, 126.9, 126.6, 124.3, 124.1, 122.8,
117.8, 112.9, 99.6, 99.4, 57.0, 43.8, 38.4, 24.8. Anal. Calcd for
C30H33Cl2N7O6: C, 54.72; H, 5.05; Cl, 10.77; N, 14.89; O, 14.58.
Found: C, 54.80; H, 5.01; N, 14.92.
5·2HCl. Yield = 18.9%; dark-violet solid; mp dec >200 °C. 1H NMR
(300 MHz, CD3OD): 8.00 (s, 1H), 7.87 (d, J = 6.6 Hz, 1H), 7.79 (1H,
s), 7.0 (d, J = 6.5 Hz, 1H), 3.98 (bs, 4H), 3.14 (m, 4H), 2.83 (s, 12H),
2.01 (m, 4H). 13C NMR (75 MHz, CD3OD):162.0, 161.0, 144.6,
141.4, 140.7, 132.1, 127.1, 124.1, 122.9, 122.1, 121.2, 120.7, 118.9,
111.9, 55.1, 48.7, 46.5, 42.6, 37.5, 37.2, 22.5, 22.4. Anal. Calcd for
C30H32BrCl2N7O6: C, 48.86; H, 4.37; Br, 10.84; Cl, 9.61; N, 13.30; O,
13.02. Found: C, 48.79; H, 4.31; N, 13.22.
8·2HCl. Yield = 18%; dark-violet solid; mp dec >200 °C. 1H NMR
(400 MHz, CD3OD): 7.85 (s, 1H), 7.76 (s, 1H), 7.20 (m, 1H), 6.95
(bs, 1H), 3.91 (m, 4H), 2.70 (m, 4H), 2.52 (m, 12H), 1.93 (m, 4H).
13C NMR (100 MHz, CD3OD):165.8, 162.5, 161.5, 146.5, 143.8,
141.9, 133.2, 128.7, 125.5, 125.1, 123.4, 123.1, 121.9, 120.5, 97.8, 57.9,
45.2, 45.1, 39.9, 39.7, 26.0, 25.9. Anal. Calcd for C29H32BrCl2N7O4: C,
50.23; H, 4.65; Br, 11.52; Cl, 10.22; N, 14.14; O, 9.23. Found: C,
50.17; H, 4.71; N, 14.08.
Synthesis of 6 and 7. NDI 1 (0.5 mmol) was dissolved into 40 mL
of CH3CN in a round-bottom ﬂask together with 1.0 mmol of 3,4-
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diaminobenzoic acid, the mixture was stirred at 85 °C for 72 h under
argon. The resulting dark-violet solution was cooled at r.t. to induce
precipitation of the product. The crude powder was ﬁltered and
puriﬁed by HPLC chromatography, (CH3CN:H2O 0.1%TFA)
according to analytical method A and preparative method B, aﬀording
the title NDIs 6 (27%) and 7 (30.5%).
6·2HCl. Yield = 27%; dark-violet solid; mp dec >200 °C. 1H NMR
(400 MHz, CD3OD): 7.86 (s, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.39 (s,
1H), 6.89 (d, J = 8.0 Hz, 1H), 4.16 (m, 4H), 3.26 (m, 4H), 2.95 (s,
12H), 2.16 (m, 4H). 13C NMR (100 MHz, CD3OD):168.2, 166.6,
166.5, 164.3, 164.2, 143.1, 142.8, 132.6, 129.8, 129.2, 128.6, 127.0,
126.7, 126.6, 126.4, 123.6, 123.5, 119.0, 117.7, 98.3, 97.7, 57.0, 43.8,
40.7, 38.4; 24.8. Anal. Calcd for C31H34Cl2N6O6: C, 56.63; H, 5.21; Cl,
10.78; N, 12.78; O, 14.60. Found: C, 56.77; H, 5.31; N, 12.72.
7·2HCl. Yield = 30.5%; dark-violet solid; mp dec >200 °C. 1H NMR
(300 MHz, CD3OD): 8.37 (s, 2H), 7.85 (d, J = 8.0 Hz, 1H), 7.73 (s,
1H), 7.21 (d, J = 8.0 Hz, 1H), 4.35 (m, 4H), 3.41 (m, 4H), 3.05 (s,
12H), 2.29 (m, 4H). 13C NMR (75 MHz, CD3OD): 168.3, 166.2,
163.5, 161.8, 161.7, 160.8, 152.2, 133.2, 132.6, 130.1, 129.4, 126.5,
123.4, 123.3, 121.6, 119.12, 118.21, 117.9, 98.3, 97.6, 57.04, 43.9, 38.3,
38.5, 24.8, 24.7. Anal. Calcd for C31H33BrCl2N6O6: C, 50.56; H, 4.52;
N, 11.41; O, 13.03. Found: C, 50.34; H, 4.61; N, 11.29
Microwave Assisted (MW) Nucleophilic Aromatic Substitution:
Synthesis of 9. Compound 3 (0.5 mmol) was dissolved into 4 mL of
N,N-dimethyl-propan-1,3-diamine. The mixture was stirred and heated
in a microwave reactor, according to a closed vessel protocol, at 150
°C, 250 psi, 200 W, for 3 min. The resulting green solution was cooled
at rt to induce precipitation of the product. The resulting deep-green
powder was ﬁltered and washed by water aﬀorded 1 (Yield 92%).
Further HPLC preparative puriﬁcation (CH3CN:H2O and 0.1%
CF3COOH as eluent), and ﬁnal triﬂuoroacetate-chloride anion
exchange, by addition of 1 mL HCl 1M, yielded 9 as trihydrochloride
(9·3HCl); deep-green solid; mp dec >200 °C. 1H NMR (300 MHz,
CD3OD): δ = 7.10 (m, 1H), 6.96 (m, 2H), 6.69 (m, 2H), 4.11 (m,
4H), 3.42 (m, 2H), 3.26 (m, 6H), 2.99 (s, 6H), 2.93 (s, 12H), 2.18
(bs, 2H), 2.11 (bs, 4H). 13C NMR (75 MHz, CD3OD): δ = 166.7,
166.4, 164.5, 144.2, 139.7, 129.8, 129.0, 128.9, 127.5, 126.6, 125.0,
117.6, 117.1, 115.8, 108.2, 104.5, 98.1, 97.7, 63.4, 57.0, 54.0, 53.8, 43.8,
41.1, 38.5, 38.1, 25.7, 24.9, 24.8, 24.1. Anal. Calcd for C35H47Cl3N8O4:
C, 56.04; H, 6.32; Cl, 14.18; N, 14.94; O, 8.53. Found: C, 56.17; H,
6.39; N, 14.90.
Exhaustive Methylation: Synthesis of 10 and 11. The c-exNDIs
(2 or 3) puriﬁed as hydrochlorides were dissolved in a NaHCO3
solution and extracted 3 times with CH2Cl2. The recovered organic
layers have been dried on Na2SO4 and the solvent evaporated under
reduced pressure. The collected amine (2.5 mmol) was suspended in
50 mL of CHCl3 and 1.2 g (8.5 mmol) of CH3I were added. This
suspension was stirred under nitrogen atmosphere, at room temper-
ature for 12 h. After this period the resulting dark-violet powder was
ﬁltered and dried, aﬀorded the product as pure di-iodide salt.
10. Yield = 99%; dark-violet crystals; mp dec >200 °C. 1H NMR
(400 MHz, CD3OD): δ = 7.94 (s, 2H), 7.12 (dd, J = 3.3, 6.0 Hz, 2H),
6.97 (dd, J = 3.3, 6.0 Hz, 2H), 4.14 (m, 4H), 3.49 (m, 4H), 3.15 (m,
18H), 2.21 (m, 4H). 13C NMR (100 MHz, D2O): δ = 166.9, 165.8,
143.8, 129.1, 128.1, 127.6, 126.3, 123.5, 118.3, 97.5, 66.1, 54.1, 38.6,
23.6. Anal. Calcd for C32H38I2N6O4: C, 46.62; H, 4.65; I, 30.78; N,
10.19; O, 7.76. Found: C, 46.53; H, 4.59; N, 10.22.
11. Yield = 99%; dark-violet crystals; mp dec >200 °C. 1H NMR
(400 MHz, CD3OD): δ = 8.04 (s, 1H), 7.15 (bs, 2H), 7.00 (bs, 2H),
4.12 (m, 4H), 3.51 (m, 4H), 3.15 (s, 18H), 2.20 (bs, 2H). 13C NMR
(100 MHz, CD3OD): δ = 166.3, 165.9, 163.2, 162.2, 145.1, 144.1,
143.0, 132.5, 130.1, 128.8, 128.7, 128.3, 128.2, 126.4, 123.0, 121.1,
120.2, 118.3, 118.2, 96.9, 65.8, 53.9, 38.8, 38.6, 23.3, 23.2. Anal. Calcd
for C32H37BrI2N6O4: C, 42.55; H, 4.13; Br, 8.84; I, 28.09; N, 9.30; O,
7.08. Found: C, 42.60; H, 4.18; N, 9.39.
Spectroscopic Techniques (FRET and CD). All oligonucleotides
used in this study were from Sigma-Aldrich (Milan, Italy). For
ﬂuorescence melting curves, equimolar amounts of the compounds
were added to each FAM (6-carboxyﬂuorescein) 5′-end- and TAMRA
(6-carboxy-tetramethylrhodamine) 3′-end-labeled oligonucleotide
(0.25 uM) folded in the lithium cacodylate buﬀer supplemented
with potassium (100 mM). After stabilization at 4 °C, samples were
processed in a LightCycler II (Roche, Milan, Italy) or LightCycler 480
(Roche, Milan, Italy), and the oligonucleotide melting was monitored
by observing 6-carboxyﬂuorescein (6-FAM) emission in the temper-
ature range of 30− 95 °C with 1 °C/min gradient. Melting proﬁles
were normalized as previously described.66 Tm was deﬁned as the
temperature corresponding to the 0.5 fraction of the normalized
ﬂuorescence.
For CD analysis, oligonucleotides were diluted to a ﬁnal
concentration of 4 μM in lithium cacodylate buﬀer (10 mM, pH
7.4) and KCl 100 mM. After annealing step (95 °C for 5 min), DNA
samples were gradually cooled to room temperature and compounds
added from stock at ﬁnal concentration of 16 μM. CD spectra were
recorded on a Chirascan-Plus (Applied Photophysisics, Leatherhead,
UK) equipped with a Peltier temperature controller using a quartz cell
of 5 mm optical path length and an instrument scanning speed of 50
nm/min over a wavelength range of 230−320 nm. The reported
spectrum of each sample represents the average of 2 scans is baseline-
corrected for signal contributions due to the buﬀer. Observed
ellipticities were converted to mean residue ellipticity (θ) = deg ×
cm2 × dmol−1 (mol ellip). For the determination of Tm, spectra were
recorded over a temperature range of 20−95 °C, with temperature
increase of 5 °C/min. Tm values were calculated according to the van’t
Hoﬀ equation, applied for a two-state transition from a folded to
unfolded state, assuming that the heat capacity of the folded and
unfolded states are equal.67
Taq Polymerase Stop Assay. Taq polymerase stop assay was
carried out as previously described.27,30 Brieﬂy, the 5′-end labeled
primer was annealed to its template (Supporting Information, Table
S1) in lithium cacodylate buﬀer in the presence or absence of KCl 100
mM and by heating at 95 °C for 5 min and gradually cooling to room
temperature. Where speciﬁed, samples were incubated with 2 (3.1−
25.0 nM). Primer extension was conducted with 2 U of AmpliTaq
Gold DNA polymerase (Applied Biosystem, Carlsbad, California,
USA) at 47 °C for 30 min. Reactions were stopped by ethanol
precipitation, primer extension products were separated on a 15%
denaturing gel, and ﬁnally visualized by phosphorimaging (Typhoon
FLA 9000).
Mass Spectrometric (MS) Competition Assay. Oligonucleo-
tides were heat-denatured and folded in 10 mM KCl, 150 mM
trimethylammonium acetate (TMAA), pH 6.8, overnight at room
temperature. The oligonucleotides where diluted to ﬁnal concentration
of 10 μM and incubated with the tested compound at ratio
DNA:compound 1:1 overnight at 4 °C.
Samples were analyzed by direct infusion electrospray ionization
(ESI) on a Xevo G2-XS QTof mass spectrometer (Waters,
Manchester, UK). The injection was automatically performed by an
Agilent 1290 Inﬁnity HPLC (Agilent Technologies, Santa Clara, CA,
US) equipped with an auto sampler; the carrying buﬀer was TMAA
100 mM. The absence of potassium in the carrying buﬀer allows the
dilution of the salts before MS analysis decreasing the signal
suppression. Up to 5 μL samples were typically injected for each
analysis. The electrospray capillary was at 1.8 kV, the source and
desolvation temperatures were 45 and 65 °C, respectively, and the
sampling cone was at 65 V. All these parameters ensured minimal
fragmentation of the DNAs complexes. The instrument was calibrated
using a 2 mg/mL solution of sodium iodide in 50% 2-propanol.
Additionally, the use of the LockSpray during the analysis provided a
typical <2 ppm mass accuracy. The internal standard LockSpray
consisted in a solution of leu-enkephalin 1 μg/mL in acetonitrile/water
(50:50, v/v) containing 0.1% formic acid. Binding aﬃnities were
calculated for each experiment using the reconstructed-ion chromato-
gram area for each species calculated by MassLynx V4.1: this analysis
was made possible by the experimental design that used an HPLC
system to inject the samples in the mass spectrometer. The binding
aﬃnity was calculated with the following formula: [BA = (ΣG4b/
(ΣG4f + ΣG4b)) × 100], where BA is the binding aﬃnity, G4b is
chromatogram area of bound G4 DNA, and G4f is the chromatogram
area of free G4 DNA.68 G4b comprises DNA with one or two bound
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ligands, where present. Signals with charge states 6−, 5−, and 4− were
used for the free and bound hTel DNA and c-myc, charge states 6−
and 5− for LTR-III, charge states 5− and 4− for c-kit2, and charge state
4− for LTR-IV. Free DNA mono and dipotassium adducts were
included in the calculation. For stoichiometric calculation, oligonu-
cleotides were folded in 10 mM KCl, 150 mM TMAA pH 6.8
overnight at rt. The oligonucleotides, diluted to ﬁnal concentration of
10 μM, were incubated with the tested compound (ratio 1:5, 1:10,
1:20, and 1:50) at 4 °C and analyzed by ESI-MS.
SPR Analysis. SPR was performed on the Biacore T100 platform
(GE Healthcare). 5′-Biotinylated LTR-III, LTR-IV, and hTel
oligonucleotides were heated at 95 °C for 5 min and cooled down
at room temperature to allow G4 folding. Immobilization was
performed in HEPES-KCl running buﬀer (0.01 M HEPES pH 7.4,
0.2 M KCl, 3 mM EDTA) on a steptavidin coated surface (SA sensor
chip, Biacore). Oligonucleotides were diluted in HEPES-KCl running
buﬀer to a concentration of 30 nM and injected to reach the response
of around 500 RU. Flow cell 1 was left empty to allow reference
subtraction. C-exNDIs binding analysis was performed at a ﬂow rate of
30 μL/min, with contact time of 280 s and dissociation time of 360 s
in HEPES-KCl buﬀer. Sensorgrams were obtained in the concen-
tration range of 25−200 nM. After each compound injection the chip
surface was regenerated with glycine 10 mM pH 2.0 solution (GE
Healthcare). All sensorgrams were corrected by buﬀer injection
response. Data were ﬁtted to a 1:1 binding model with Rmax initial
parameter set to theoretical calculated Rmax using BIAevaluation
software (GE Healthcare). All experiments were performed
independently at least twice, and in each instance χ2 values, which
indicate the goodness of ﬁtting, were below 0.2.
CL-Mediated Footprinting. All oligonucleotides were gel-puriﬁed
before use and prepared in desalted/lyophilized form. Oligonucleo-
tides were 5′-end-labeled with [γ- 32P]ATP by T4 polynucleotide
kinase and puriﬁed by MicroSpin G-25 columns (GE Healthcare,
Europe). They were next resuspended in lithium cacodylate 10 mM,
pH 7.4, and KCl 100 mM, heat-denatured, and folded. Reactions of
the labeled G-quadruplex folded oligonucleotides (4 pmol/sample)
with increasing amounts of compound 2 (4−100 nM) were performed
at 20 °C for 24 h in resuspension buﬀer. Samples were then reacted
with CL (100 μM) at 37 °C for 24 h. Reactions were stopped by
ethanol precipitation, resuspended, and either kept on ice or treated at
90 °C for 30 min with 1 M piperidine to complete strand scission
according to the Maxam and Gilbert protocol. Samples were then
lyophilized, resuspended in formamide gel loading buﬀer, and heated
at 95 °C for 3 min. Reaction products were analyzed on 20%
denaturing polyacrylamide gels and visualized by Typhoon FLA 9000
phosphorimaging analysis (GE Healthcare).
Reporter Assays. The HIV-1 promoter activity in live cells in the
presence of 2 was monitored in HeLa-Tat-III/LTR/d1EGFP cells
(obtained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH, from Dr. Satoh). This cell line derives from HeLa-tat-III
and is transfected with d1EGFP under the control of HIV-1 LTR
promoter. Then 8 ×104 of HeLa-Tat-III/LTR/d1EGFP cells were
seeded in a 12-well plate in 1 mL of DMEM/10% FBS medium
supplemented with Geneticin selective antibiotic (1 mg/mL, Life
Technologies, Monza, Italy) and incubated overnight. Cells were next
treated with increasing concentrations of 2 (0−62.5−125−250 nM)
and incubated at 37 °C. After 48 h, cells were washed with PBS 1× and
resuspended in 500 μL of PBS 1×. To evaluate the mean of EGFP
ﬂuorescence, a total of 10000 events were acquired for each sample
with an LRS 2 instrument using FACS DIVA Software (BD
Bioscience) and analyzed with Flow Jo (Tree Star). Cell debris and
dead cells were excluded from the analysis by gating on forward scatter
(FSC) versus side scatter (SSC) and were quantiﬁed to estimate the
cytotoxicity.
For the luciferase assay, HIV-1 LTR region (wt or M4 + 5) was
inserted into the promoterless luciferase reporter vector pGL4.10-Luc2
(Promega Italia, Italy), as previously reported.27 For assessment of
luciferase activity, human embryonic kidney 293T (HEK293T) cells
were seeded in a 24-well plate (9 × 104 cells/well). Then 24 h later,
cells were transfected with 100 ng/well of pGL4.10-LTRwt or of
pGL4.10-LTR-M4 + 5 using TransIT-293 transfection reagent (Mirus
Bio LLC, Madison, WI, USA), according to the manufacturer’s
protocol. After 1 h, cells were treated with 2 for 24 h at various
concentrations. Luciferase activity was measured using the britelite
plus Reporter Gene Assay System (PerkinElmer Inc., Milan, Italy) at a
Victor X2 multilabel plate reader (PerkinElmer Inc., Milan, Italy),
according to the manufacturer’s instructions. Cells were lysed in RIPA
buﬀer (50 mM Tris-HCl pH 7.2, 150 mM NaCl, 1% Igepal, 0.1%
SDS) and protein concentration was determined by BCA assay
(Thermo Scientiﬁc Pierce, Monza, Italy). Luciferase signals were
subsequently normalized to total protein content, according to the
manufacturer’s protocol (http://ita.promega.com/~/pdf/resources/
pubhub/cellnotes/normalizing-genetic-reporter-assays/).
Antiviral Assay in HIV-1 Infected TZM-bl Cells. HIV-1
infectivity was measured using the TZM-bl reporter cell line (obtained
through the NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH, from Dr. J.C. Kappes, Dr. X. Wu, and Tranzyme Inc.). TZM-bl is
a HeLa cell line stably expressing large amounts of CD4 and CCR5
and containing integrated copies of the luciferase and β-galactosidase
genes under control of the HIV-1 promoter. TZM-bl were grown in
DMEM supplemented with 10% FBS. Cells (1 ×104 cells/well) were
seeded in 96-well plates and grown overnight to permit adherence
prior to treatment and viral infection. Cells were next infected with
HIV-1 NL4-3 strain or BaL strain at a MOI of 0.5, treated with serial
dilutions of tested compounds, and incubated at 37 °C. After 48 h,
cells were washed with PBS 1× and HIV-1 production was assessed
following the LTR-luciferase signal using the britelite plus Reporter
Gene Assay System (PerkinElmer, Waltman, MA, USA) according to
the manufacturer’s protocol.
Cytotoxicity Assay. Cytotoxicity of tested compounds was tested
in parallel to antiviral and reporter assays by MTT. The 50% cytotoxic
concentration (CC50) was deﬁned as the concentration of test
compound that was able to reduce the absorbance of the mock-
infected cells by 50%. The 50% inhibitory concentration (IC50) was
deﬁned as the concentration of test compound that inhibit 50% of
LTR-Luciferase signal. The selectivity index (SI) is the relative
eﬀectiveness of the tested compound in inhibiting viral replication
compared to inducing cell death (CC50 value/IC50 value). The
therapeutic window (TW) is the concentration range at which the
compound shows antiviral activity paralleled by less than 80%
cytotoxicity.
HIV-1 Entry Assay. TZM-bl cells (1 × 104 cells/well) were seeded
in 96-well plates and grown overnight to permit adherence prior to
treatment and viral infection. Cells were next infected with HIV-1
NL4-3 (MOI 0.5) and incubated at 37 °C. Compound 2 (50−100
nM) and the reference compounds DS (100 μg/mL, Sigma-Aldrich)
and AZT (0.5 μg/mL, Sigma-Aldrich) were added at diﬀerent hours
(0, 1, 2 h) pi. After 31 h, cells were washed with PBS 1× and HIV-1
production was assessed following the LTR-luciferase signal using the
britelite plus Reporter Gene Assay System (PerkinElmer, Waltman,
MA, USA) according to the manufacturer’s protocol.
Computational Method. DFT calculations were performed with
the Gaussian 09, revision B.01 software package.69 Gas-phase
geometry optimizations were carried out using the B3LYP func-
tional,70 with 6-31+G(d,p) basis set for all the atoms.
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